WO2008107910A3 - Use of caralluma extracts in the inhibition of adipogenesis and a method of inhibition for the same - Google Patents

Use of caralluma extracts in the inhibition of adipogenesis and a method of inhibition for the same Download PDF

Info

Publication number
WO2008107910A3
WO2008107910A3 PCT/IN2008/000123 IN2008000123W WO2008107910A3 WO 2008107910 A3 WO2008107910 A3 WO 2008107910A3 IN 2008000123 W IN2008000123 W IN 2008000123W WO 2008107910 A3 WO2008107910 A3 WO 2008107910A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibition
adipogenesis
obesity
complex
action
Prior art date
Application number
PCT/IN2008/000123
Other languages
French (fr)
Other versions
WO2008107910A2 (en
Inventor
Ramaswamy Rajendran
Kamala Rajendran
Mohammed Abdulkader Akbarsha
Ramasamy Varadarajan Venkatesh
Original Assignee
Ramaswamy Rajendran
Kamala Rajendran
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramaswamy Rajendran, Kamala Rajendran filed Critical Ramaswamy Rajendran
Publication of WO2008107910A2 publication Critical patent/WO2008107910A2/en
Publication of WO2008107910A3 publication Critical patent/WO2008107910A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Inhibition of adipogenesis by the pregnane glycosides(PGs)(or by caralluma extracts) is disclosed. Said inhibition occurs early in the cell cycle which substantially comes to rest at the G1 phase, the action being by the inhibition of the formation of the cyclin D1-CDK 4/6 complex, the prevention of the translocation of said complex into the nucleus and enhancement of the action of cell division inhibitory factors arising during the cell division process in 3T3-L1 cell lines. PG mixtures(including isomer mixtures) exhibit synergy, the preferred mixture being that of the caratubersides and boucerosides in the ratio 9: 1 to 19: 1 w/w. Applications include said inhibition, the treatment/management of obesity and obesity-related disorders, the regulation of obesity-related parameters such as weight, b.p., cholesterol, blood sugar and others and preventing the weight exceeding the critical limit whereat said adipogenesis is triggered in human and animal subjects.
PCT/IN2008/000123 2007-03-05 2008-03-03 Use of caralluma extracts in the inhibition of adipogenesis and a method of inhibition for the same WO2008107910A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN432/CHE/2007 2007-03-05
IN432CH2007 2007-03-05

Publications (2)

Publication Number Publication Date
WO2008107910A2 WO2008107910A2 (en) 2008-09-12
WO2008107910A3 true WO2008107910A3 (en) 2009-10-08

Family

ID=39738906

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000123 WO2008107910A2 (en) 2007-03-05 2008-03-03 Use of caralluma extracts in the inhibition of adipogenesis and a method of inhibition for the same

Country Status (1)

Country Link
WO (1) WO2008107910A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106928299A (en) * 2015-12-31 2017-07-07 中国医学科学院药物研究所 One class derives from the compound of the root bark of Chinese wolf-berry, its preparation method and the application in terms of hypoglycemic

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108148A1 (en) * 2003-06-04 2004-12-16 Ramaswamy Rajendran Processes for making caralluma extracts and uses
WO2005102371A2 (en) * 2004-04-27 2005-11-03 Ramaswamy Rajendran Use of the pregnane glycosides in the treatment/management of obesity, obesity-related and other disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108148A1 (en) * 2003-06-04 2004-12-16 Ramaswamy Rajendran Processes for making caralluma extracts and uses
WO2005102371A2 (en) * 2004-04-27 2005-11-03 Ramaswamy Rajendran Use of the pregnane glycosides in the treatment/management of obesity, obesity-related and other disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KURIYAN ET AL: "Effect of Caralluma Fimbriata extract on appetite, food intake and anthropometry in adult Indian men and women", APPETITE, ACADEMIC PRESS, NEW YORK, NY, US, vol. 48, no. 3, 13 November 2006 (2006-11-13), pages 338 - 344, XP005926963, ISSN: 0195-6663 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106928299A (en) * 2015-12-31 2017-07-07 中国医学科学院药物研究所 One class derives from the compound of the root bark of Chinese wolf-berry, its preparation method and the application in terms of hypoglycemic
CN106928299B (en) * 2015-12-31 2021-04-13 中国医学科学院药物研究所 Compound from cortex lycii radicis, preparation method and application thereof in aspect of reducing blood sugar

Also Published As

Publication number Publication date
WO2008107910A2 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
Xue et al. Trigonella foenum graecum seed extract protects kidney function and morphology in diabetic rats via its antioxidant activity
Edaravone Acute Infarction Study Group Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters
JP2022190124A (en) Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
Corona et al. Hypogonadism as a possible link between metabolic diseases and erectile dysfunction in aging men
CA2884898C (en) Pharmaceutical composition comprising palmitoylethanolamide and l-acetylcarnitine
MY160894A (en) Oligosaccharide composition for treating skin diseases
WO2008050329A3 (en) Novel sirnas and methods of use thereof
RU2608442C2 (en) Use of meadowsweet (filipendula) extracts for treating and preventing chronic pain
Pannacci et al. Panax ginseng CA Mayer G115 modulates pro-inflammatory cytokine production in mice throughout the increase of macrophage toll-like receptor 4 expression during physical stress
Invernizzi et al. Rethinking the clinical management of volumetric muscle loss in patients with spinal cord injury: Synergy among nutritional supplementation, pharmacotherapy, and rehabilitation
US20080085332A1 (en) Methods and compositions for improving cardiovascular risk factors and metabolic risk factors that cause syndrome x
Wang et al. Alpinumisoflavone protects against glucocorticoid-induced osteoporosis through suppressing the apoptosis of osteoblastic and osteocytic cells
WO2007096739A3 (en) Intestinal alpha-glucosidase inhibitors and a process for the isolation and use thereof
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
US20240024353A1 (en) Methods and compositions for extending lifespan
WO2008107910A3 (en) Use of caralluma extracts in the inhibition of adipogenesis and a method of inhibition for the same
US10537603B2 (en) Pharmaceutical composition for preventing or treating angioedema, containing extract of peony root or mixture of peony root and licorice as active ingredient
Singhal et al. Pharmacological evaluation of “sugar remedy,” a polyherbal formulation, on streptozotocin-induced diabetic mellitus in rats
Magnone et al. Fluridone as a new anti-inflammatory drug
Makbul et al. Scientific appraisal of urolithiasis and its remedial measures in Unani medicine
Pouyamanesh et al. Effect of inulin supplementation in male mice fed with high fat diet on biochemical profile and α-amylase gene expression
Zhang et al. Effect of dehydroepiandrosterone on atherosclerosis in postmenopausal women
KR20190014700A (en) The Inhibitory Effects of Amomum vilosum Loureiro Extracts and Composition Containing the Extract as Effective Ingredient
JP5871227B2 (en) Antiallergic dermatitis topical agent
WO2004062626A3 (en) Composition and method for treating age-related disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08751422

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08751422

Country of ref document: EP

Kind code of ref document: A2